Cataract

The Kansas-based company specializes in ophthalmic surgical equipment and services.

The second issue of the 2023 Video Journal of Cataract, Refractive, & Glaucoma Surgery offers a compilation of 27 surgical highlights from the ESCRS meeting in Milan, providing valuable education for global anterior segment surgeons.

Orbis International physician spotlights the latest trends for cataract surgery training.

An expert discusses how to ensure optimal administration.

Surgeons must use caution to avoid pitfalls of complicated procedure

Results of the Alcon Eye on Cataract Survey highlight misconceptions about cataract surgery, revealing the need to educate the 50+ population on the procedure and treatment options.

The organization aims to educate patients and doctors on one of the leading causes of blindness worldwide.

The day helps to bring focus and awareness to risk factors for early vision loss associated with smoking.

According to the company, study results show sustained reductions in both IOP and glaucoma medication use in mild-moderate primary open angle glaucoma patients treated with a procedure enabled with the OMNI Surgical System technology.

With instructor-led sessions and haptic feedback, this first-of-its-kind eye surgery training creates an immersive experience with the look and feel of surgery in a human eye, without risks to patient safety.

According to the company, StableVisc and TotalVisc offer surgeons dual-action protection during cataract surgery.

Lisa M. Nijm, MD, MD, highlights what residents, fellows, and ophthalmologists who are early in their careers can expect at the virtual Real World Ophthalmology meeting on Saturday, April 15.

Evolving technology is resulting in better outcomes for patients.

The first 2023 release of the Video Journal of Cataract, Refractive, & Glaucoma Surgery explores essential techniques for intraocular lens (IOL) removal, providing a diverse range of both routine and novel approaches within its hour-long presentation.

Procedure integrates femto, phaco in one instrument to address issues.

The company’s MINIject is the only commercially available MIGS implant targeting the supraciliary space.

According to the company, in a clinical trial of chloroprocaine hydrochloride ophthalmic gel in patients undergoing routine cataract surgery, patients treated with the gel did not require any supplemental treatment to complete the intended surgical procedure.

Outcomes achieved with information, osmolarity testing, proven treatments

The study compared 126 IOL injectors of 13 IOL injector systems regarding the manufacturers’ recommended preoperative incision sizes to evaluate the intraoperative incision enlargement and postoperative incision sizes.

Surgeon notes there is no good solution for ending use of topical medications

Bonnie An Henderson, MD, founder and program director of EnVision Summit, previews what attendees can expect at this year’s meeting - from its diverse faculty to an inclusive Youth Program, while also giving back to the community. The conference will take place February 17 to 20 at the El Conquistador Resort in Fajardo, Puerto Rico.

In preclinical models, investigators at Brigham and Women’s Hospital uncovered a novel mechanism underlying the development of diabetic cataracts that undermines current hypothesis

Terms for the deal for AcuFocus were not revealed by the companies.

According to the company, the facility will serve as a hub of the EVO Lens-Based Experience for ophthalmic surgeons, staff and healthcare practitioners.

In a two-decade career as a researcher at Johnson & Johnson Surgical Vision, Piers has been a part of teams at the forefront of a number of innovations in IOLs. She discusses her career and the outlook for research and development in ophthalmology.

According to physicians, patients who do not undergo second procedure are more likely to develop glaucoma.

The deal will provide Harrow’s entire formulary compounded ophthalmic products to iOR Partners’ expanding office-based surgery locations across the United States.

Investigators find a link with a postoperative prolonged steroid response.

The SBL-3 ClearView clinical study, an FDA investigational device exemption clinical trial conducted at 18 sites across the US, is a prospective, subject-masked, randomized, two-arm study.